Users Online: 195
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
THE GREAT DEBATE: FOR HPV VACCINE IN CERVICAL CANCER
Year : 2013  |  Volume : 2  |  Issue : 4  |  Page : 187-192

Efficacy and safety of human papillomavirus vaccine for primary prevention of cervical cancer: A review of evidence from phase III trials and national programs


1 Department of Gynaecologic Oncology, Chittaranjan National Cancer Institute, Kolkata, West Bengal, India
2 Department of Surgical Oncology, Chittaranjan National Cancer Institute, Kolkata, West Bengal, India

Correspondence Address:
Partha Basu
Department of Gynaecologic Oncology, Chittaranjan National Cancer Institute, Kolkata, West Bengal
India
Login to access the Email id

Source of Support: None, Conflict of Interest: Declaration of Dr. Partha Basu has been a member of the advisory boards of both GlaxoSmithKline and Merck. He has been principal investigators for two HPV vaccine trials sponsored by GlaxoSmithKline.


DOI: 10.4103/2278-330X.119877

Rights and Permissions

The Human Papillomavirus (HPV) vaccines have been widely introduced in the national immunization programs in most of the medium and high income countries following endorsement from national and international advisory bodies. HPV vaccine is unique and its introduction is challenging in many ways - it is the first vaccine developed to prevent any cancer, the vaccine is gender specific, it targets adolescent females who are difficult to reach by any health intervention programs. It is not unusual for such a vaccine to face scepticism and reservations not only from lay public but also from professionals in spite of the clinical trial results convincingly and consistently proving their efficacy and safety. Over the last few years millions of doses of the HPV vaccine have been administered round the world and the efficacy and safety data have started coming from the real life programs. A comprehensive cervical cancer control program involving HPV vaccination of the adolescent girls and screening of the adult women has been proved to be the most cost-effective approach to reduce the burden of cervical cancer. The present article discusses the justification of HPV vaccination in the backdrop of natural history of cervical cancer, the mechanism of action of the vaccines, efficacy and safety data from phase III randomized controlled trials as well as from the national immunization programs of various countries.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2539    
    Printed44    
    Emailed0    
    PDF Downloaded658    
    Comments [Add]    
    Cited by others 10    

Recommend this journal